NCT05598736View on ClinicalTrials.gov

Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain

NAUnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 4, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

December 31, 2023

Conditions
Multiple SclerosisSpasticity, MusclePain
Interventions
DEVICE

FlowOx 2.0

-40mmHg intermittent negative pressure for 60 minutes per day

Trial Locations (1)

5839

Dept. of Neurology Haukeland Univ. Hospital & Dept. of Clin. Med., Univ. of Bergen, Bergen, Norway, Bergen

Sponsors

Lead Sponsor

Otivio AS
All Listed Sponsors
lead

Otivio AS

INDUSTRY

NCT05598736 - Performance and Long-term Safety of FlowOx2.0™, Multiple Sclerosis, Spasticity and Pain | Biotech Hunter | Biotech Hunter